HEMLIBRA® was studied in the HAVEN 3 clinical trial, in adults and adolescents aged ≥12 years with hemophilia A without factor VIII inhibitors. To learn more about the study design, please visit the Clinical Trials Overview.
HAVEN 3 efficacy results
Primary endpoint: Significant reduction in treated bleed rate
with HEMLIBRA vs no prophylaxis in patients without FVIII
inhibitors
As demonstrated in a prospective intra-patient comparison: The first and only treatment to show a significant reduction in treated bleed rate vs prior prophylaxis in patients without FVIII inhibitors 6-13
As observed over at least 24 weeks (HAVEN 3): Sustained protection meant 0 treated bleeds for most patients
Significantly more patients had 0 bleeds with HEMLIBRA vs prior FVIII prophylaxis or no prophylaxis.
ABR=annualized bleed rate; CI=confidence interval;
FVIII=factor VIII; IQR=interquartile range.
*ABR was
calculated with a negative binomial regression model, accounting for
the different follow-up times.
Efficacy in Patients With Inhibitors
Learn about the primary and secondary results for patients with FVIII
inhibitors
Adverse Reactions
Adverse reactions from pooled clinical studies with HEMLIBRA
Dosing Calculator
Help calculate the dosage for your HEMLIBRA patient